Hansa Biopharma to host conference call to provide interim results for January-March 2022 and Business Update
Lund, Sweden April 8, 2022 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-March 2022 at 8:00 CET on April 21, 2022. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.
Slides used in the presentation will be live on the company website during the call under “Events & Presentations” and will also be made available online after the call. Link to presentation
To participate in the telephone conference, please use the dial-in details provided below:
Sweden: +46 10 884 80 16
United Kingdom: +44 20 3936 2999
United States: +1 646 664 1960
The webcast will be available on https://streams.eventcdn.net/hansa/q1-2022/
Updated Calendar and Events 2022
April 13, 2022 Needham Healthcare Conference 2022
April 21, 2022 Interim Report for January-March 2022
April 21, 2022 Kempen Life Sciences Conference 2022, Amsterdam
April 27, 2022 Redeye Orphan Drugs 2022, Stockholm
May 15, 2022 ABG Life Science Summit, Stockholm
May 16, 2022 European Midcap Event, Copenhagen
June 16, 2022 Annual General Meeting 2022
July 12, 2022 William Blair’s Biotech Focus Conference 2022, New York
July 21, 2022 Half year 2022 report
Aug 9, 2022 BTIG Biotechnology Conference 2022, New York
Aug 10, 2022 Canaccord Annual Growth Conference, Boston
Sept 7-8, 2022 Pareto annual healthcare conference, Stockholm
Sept 7-8, 2022 Citi's 17th Annual BioPharma Conference, Boston
Oct 20, 2022 Interim Report for January-September 2022
Nov 23, 2022 Økonomisk Ugebrev Life Science konference, Copenhagen
For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com
Katja Margell
Head of Corporate Communications
Hansa Biopharma
Mobile: +46 (0) 768-198 326
E-mail: katja.margell@hansabiopharma.com